ArticleVirchows Archiv : an international journal of pathology2025
BRAF positive Langerhans cell sarcoma arising from CALR positive myeloproliferative neoplasm: evidence of a clonal progenitor.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Langerhans cell sarcoma (LCS) is an aggressive malignant neoplasm with a Langerhans cell immunophenotype and high-grade cytological features. Occasionally, it can coexist with other hematopoietic neoplasms with proven clonal relationship. Most of these neoplasms were found to be of lymphoid origin. This phenomenon is usually explained as lineage plasticity. Although, to the best of our knowledge, the coexistence of LCS and myeloproliferative neoplasm (MPN) with proven clonal relationship has never been reported. Herein, we describe a case of a 79-year-old man with MPN, who developed LCS 2 years after original diagnosis. Biopsy and pathological evaluation revealed a high-grade malignant neoplasm, identified as LCS with expressing CD1a, langerin, and S100. The next-generation sequencing performed on skin and bone marrow biopsies showed identical mutations in ASXL1, CALR, and TET2 genes, while the LCS tumor showed an additional BRAF mutation. This case presents the case of progression of MPN to LCS supported by molecular evidence.
Indexed as
Identifiers
40915985What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.